<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM ABBOTT
LABORATORIES' 1999 THIRD QUARTER FORM 10-Q AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FORM 10-Q FILING.
</LEGEND>
<MULTIPLIER> 1,000

                             
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                         531,070
<SECURITIES>                                    99,310
<RECEIVABLES>                                2,068,985
<ALLOWANCES>                                   185,487
<INVENTORY>                                  1,417,305
<CURRENT-ASSETS>                             5,878,049
<PP&E>                                       9,654,073
<DEPRECIATION>                               4,937,539
<TOTAL-ASSETS>                              13,574,225
<CURRENT-LIABILITIES>                        4,329,007
<BONDS>                                      1,336,425
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     1,516,933
<OTHER-SE>                                   5,152,720
<TOTAL-LIABILITY-AND-EQUITY>                13,574,225
<SALES>                                      9,662,859
<TOTAL-REVENUES>                             9,662,859
<CGS>                                        4,444,416
<TOTAL-COSTS>                                4,444,416
<OTHER-EXPENSES>                               858,361<F1>
<LOSS-PROVISION>                                10,401
<INTEREST-EXPENSE>                             111,842
<INCOME-PRETAX>                              2,465,772
<INCOME-TAX>                                   690,416
<INCOME-CONTINUING>                          1,775,356
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,775,356
<EPS-BASIC>                                       1.17
<EPS-DILUTED>                                     1.15
<FN>
<F1>Other expenses consist of research and development expenses.
</FN>